These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

762 related articles for article (PubMed ID: 29725131)

  • 1. Interleukin-6: designing specific therapeutics for a complex cytokine.
    Garbers C; Heink S; Korn T; Rose-John S
    Nat Rev Drug Discov; 2018 Jun; 17(6):395-412. PubMed ID: 29725131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibiting interleukin-6 in rheumatoid arthritis.
    Choy E
    Curr Rheumatol Rep; 2008 Oct; 10(5):413-7. PubMed ID: 18817647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The IL-6/sIL-6R complex as a novel target for therapeutic approaches.
    Rose-John S; Waetzig GH; Scheller J; Grötzinger J; Seegert D
    Expert Opin Ther Targets; 2007 May; 11(5):613-24. PubMed ID: 17465721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers.
    Ho LJ; Luo SF; Lai JH
    Biochem Pharmacol; 2015 Sep; 97(1):16-26. PubMed ID: 26080005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Interleukin-6 Signaling in Clinic.
    Kang S; Tanaka T; Narazaki M; Kishimoto T
    Immunity; 2019 Apr; 50(4):1007-1023. PubMed ID: 30995492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-6 as a key player in systemic inflammation and joint destruction.
    Fonseca JE; Santos MJ; Canhão H; Choy E
    Autoimmun Rev; 2009 Jun; 8(7):538-42. PubMed ID: 19189867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy.
    Tanaka T; Narazaki M; Ogata A; Kishimoto T
    Semin Immunol; 2014 Feb; 26(1):88-96. PubMed ID: 24594001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
    Avci AB; Feist E; Burmester GR
    BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapeutic implication of IL-6 blockade.
    Tanaka T; Kishimoto T
    Immunotherapy; 2012 Jan; 4(1):87-105. PubMed ID: 22150003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Humanized antihuman IL-6 receptor antibody, tocilizumab.
    Nishimoto N; Kishimoto T
    Handb Exp Pharmacol; 2008; (181):151-60. PubMed ID: 18071945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses.
    Fujimoto M; Serada S; Mihara M; Uchiyama Y; Yoshida H; Koike N; Ohsugi Y; Nishikawa T; Ripley B; Kimura A; Kishimoto T; Naka T
    Arthritis Rheum; 2008 Dec; 58(12):3710-9. PubMed ID: 19035481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The blockade of IL-6 signaling in rational drug design.
    Adachi Y; Yoshio-Hoshino N; Nishimoto N
    Curr Pharm Des; 2008; 14(12):1217-24. PubMed ID: 18473869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Humanized anti-human IL-6 receptor antibody, tocilizumab].
    Nishimoto N
    Nihon Rinsho; 2007 Jul; 65(7):1218-25. PubMed ID: 17642235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers.
    Yao X; Huang J; Zhong H; Shen N; Faggioni R; Fung M; Yao Y
    Pharmacol Ther; 2014 Feb; 141(2):125-39. PubMed ID: 24076269
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-6/IL-6 receptor system and its role in physiological and pathological conditions.
    Mihara M; Hashizume M; Yoshida H; Suzuki M; Shiina M
    Clin Sci (Lond); 2012 Feb; 122(4):143-59. PubMed ID: 22029668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapeutic Interleukin-6 or Interleukin-6 Receptor Blockade in Cancer: Challenges and Opportunities.
    Kampan NC; Xiang SD; McNally OM; Stephens AN; Quinn MA; Plebanski M
    Curr Med Chem; 2018; 25(36):4785-4806. PubMed ID: 28707587
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders.
    Paul-Pletzer K
    Drugs Today (Barc); 2006 Sep; 42(9):559-76. PubMed ID: 17028666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Physiological effects of modulating the interleukin-6 axis.
    Schett G
    Rheumatology (Oxford); 2018 Feb; 57(suppl_2):ii43-ii50. PubMed ID: 29982781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Immunotherapy using IL-6 receptor as the target].
    Nishimoto N
    Nihon Rinsho Meneki Gakkai Kaishi; 2008 Oct; 31(5):399-404. PubMed ID: 18974624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of interleukin-6 classic- and trans-signaling on liver damage and regeneration.
    Drucker C; Gewiese J; Malchow S; Scheller J; Rose-John S
    J Autoimmun; 2010 Feb; 34(1):29-37. PubMed ID: 19717281
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.